Skip to navigation menu Skip to content
Informational Alert

Learn about progress on health equity and anti-racism efforts in Seattle Children’s second quarterly report.

Epigenetic Targeting of DIPG

The Vitanza Lab has worked to identify histone deacetylase (HDAC) inhibitors that could be used for the treatment of DIPG, DMG and other life-threatening central nervous system (CNS) tumors.

Histones bind, unwrap or wind up DNA, and play a large role in controlling what genes can be “on” vs “off.” Mutations in these histone proteins are thought to promote cancer growth by allowing cancer-inducing genes to turn “on.” Investigations addressing DMG epigenetics have identified a few promising drugs, including HDAC inhibitor (HDACi) panobinostat. Our lab uses clinically relevant DMG models to identify and validate other effective HDACi and their biomarkers of response. In a recent study, we found that histone inhibitors quisinostat and romidepsin were effective in pre-clinical DIPG animal models.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies